

**IRSN**

INSTITUT  
DE RADIOPROTECTION  
ET DE SÛRETÉ NUCLÉAIRE

# Basics in Epidemiology

EURADOS  
9th Winter school  
Milano, 11 February 2016

Dominique Laurier

*dominique.laurier@irsn.fr*



## Content

- Epidemiology of radiation-induced risks
- Study types, terms and definitions
- Risk
- Dose-risk relationship
- Limits of low dose epidemiology
- Conclusion

# Effects of exposure to ionising radiation

## Deterministic effects

- seriousness is function of the dose
- high doses ( > 500 mGy )
- early and specific effects
- threshold model  
(rash, vomiting, modification of blood formula, cataract)

Medical  
emergency

## Stochastic effects

- frequency is function of the dose
- low and medium doses
- late and non specific effects
- no threshold model  
(cancers, hereditary effects...)

Epidemiology

# Epidemiology

## Definition

Study of the **frequency and distribution of health effects** in time and space among humans, and of their **determining factors**

- Observation science (no control as in experimental studies)
- Considers directly the relevant issue (stochastic effects)

## Objectives


### Descriptive:

- Surveillance, estimation of disease rates
- Identification of groups of population with excess risk

### Analytic :

- Identification of risk factors and quantification of relative risk
- Modelling of the exposure-risk relationship

# History of epidemiological studies of ionizing radiation







## Content

- Epidemiology of radiation-induced risks
- Study types, terms and definitions
- Risk
- Dose-risk relationship
- Limits of low dose epidemiology
- Conclusion

# Objectives and types of epidemiological studies



# Protocol of a cohort study



## Advantages:


- Time sequence from exposure toward effect, all effects

## Limits:

- Expensive: follow-up on a long duration
- Limited by the proportion of lost of follow-up



# Design of a case-controls study



## Advantages:

- Less expensive than cohort studies (a few years), adapted to rare diseases

## Limits:

- Selection bias (representativeness of controls), memory bias (of past behaviours)

# Sources of information

## Identification

- Administrative files, pay-rolls,
- Population registry (evacuees, liquidators...),
- Census...

## Exposures

- Archives: dosimetric files, occupational medicine files,
- Interviews, questionnaires,
- Time spent and location, job-exposure matrix,
- Biomarkers of exposure

## Endpoints

- Mortality registry, cancer registry,
- Hospital and medical databases,
- Declaration, score,
- Biomarkers of effect

# Bias

Well-defined limitation linked to the epidemiological approach

Depends on the study design

Can be controlled from the protocol or evaluated afterward

■ **Selection bias:** the population is not representative of the source population

- Can be due to recruitment, randomisation, migration
- Problem if the selection is linked to the pathology or the exposure
- Selection of controls in a CC design, loss of follow-up in a cohort study

■ **Misclassification bias:** the exposure is not well estimated

- Can be due to memory, missing data, subjectivity
- Problem if systematic error or if it leads to large miss of information
- Memory bias in CC studies, measurement error and error propagation

■ **Confusion bias:** a third factor modifies or hides the true relationship between exposure and effect

- Confounding factor should be linked to both exposure and effect
- Collect of information on known risk factors
- Stratification of adjustment

# Ethics and data protection

## ■ Justification of research

- Agreement by an ethic committee
- Evaluation of the objectives, protocol and analysis methods

## ■ Information of the study subjects

- Information of individuals (website, newsletter...) or signed informed consent
- Possibility to have access to personal data and/or to withdraw

## ■ Protection of data

- Anonymity/confidentiality of individual data (medical or not)
- Data safety (specific disk, encryption, limited conservation...)



## Content


- Epidemiology of radiation-induced risks
- Study types, terms and definitions
- Risk
- Dose-risk relationship
- Limits of low dose epidemiology
- Conclusion

# Definition: absolute risk

**Numerator**      number of cases (morbidity) or deaths (mortality)

---

**Denominator**      number of persons at risk over a given period (person-years)



**Absolute risk or Rate:** in cases per 100,000

**Prevalence rate:** number of cases at a given time

**Incidence rate:** number of new cases over a given period

## Definition: relative risk

**Relative risk (RR):** ratio of the absolute risk in the exposed group on the absolute risk in the control group

a RR of 1 indicates an absence of excess risk

a RR of 2 indicates a doubling of the risk

a RR of 0.5 indicates a reduction of the risk by 2

**Excess relative risk (ERR):** RR minus 1.

an ERR of 0 indicates an absence of excess risk.

an ERR of 0.2 indicates an increase of 20% of the risk

**Standardised Mortality Ratio (SMR):** estimate of the RR

$$\text{SMR} = O / E$$

where O = number of observed cases

E = number of expected cases (number of cases that should be if rates were that of a reference population)

# Study of Hiroshima and Nagasaki A-bomb survivors

## The Life Span Cohort Study (LSS)


120 000 individuals alive in 1950

86 611 individuals with reconstructed dose  
high dose rate

both sexes - all ages (and *in utero*)

mortality follow-up from 1950 to 2003


50 620 deaths (58%)



radiation induced cancers  
estimates of the dose-risk relationship  
latency between exposure and increased risk  
effect of age  
non cancer diseases



# Follow-up of cancer risk




# Excess cancer mortality among A-bomb survivors

Mortality 1950-2000  
(Preston *et al.* Radiat Res 2004)


## Excess risk

/10 000



# Mortality from lung cancer among French uranium miners

(cohort study, 5000 miners, Follow-up >30 years)



[Vacquier et al. OEM 2008]

# Definition: confidence interval and significance

**Confidence interval (CI):** range of values that contains the theoretical value with a probability  $1-\alpha$  ( $\alpha$  is conventionally fixed to 5%)

For a given estimated relative risk, the CI depends on the number of cases

$$O=4, E=2 \quad \Rightarrow \quad \text{SMR}=2 \quad \text{CI}_{95\%}=[0.54 - 5.12]$$

$$O=1000, E=500 \quad \Rightarrow \quad \text{SMR}=2 \quad \text{CI}_{95\%}=[1.88 - 2.13]$$

**Significance (p) :** a RR is significant different from 1 if the probability to wrongly reject the hypothesis of no difference is lower than 5%


$$O=4, E=2 \quad \Rightarrow \quad \text{SMR}=2 \quad p=0.14, \text{ not significant}$$

$$O=1000, E=500 \quad \Rightarrow \quad \text{SMR}=2 \quad p<0.001, \text{ significant}$$

# Definition : statistical power

**Capacity of a study to demonstrate an excess risk if it exists (probability)**

- ↗ with the size of the effect
- ↗ with the number of expected cases, and therefore with the size of the studied population (number and duration)






## Content

- Epidemiology of radiation-induced risks
- Study types, terms and definitions
- Risk
- **Dose-risk relationship**
- Limits of low dose epidemiology
- Conclusion

# Quantifying the dose-risk relationship



"Which line do you like best ?"

# Modelling the dose-risk relationship

## Models

Linear (L)


$$Y = \alpha + \beta_1 * D$$

Quadratic (Q)

$$Y = \alpha + \beta'_2 * D^2$$

Linear-quadratic (LQ)

$$Y = \alpha + \beta_1 * D + \beta_2 * D^2$$





# Risk models

## Relative risk

$$RR(d) = \frac{\lambda(c, s, b, a, e, d)}{\lambda_0(c, s, b, a)}$$

*c* city  
*s* sex  
*b* birthyear  
*a* attained age  
*e* age at exposure  
*d* dose

## Linear ERR model with modifying factors

$$\lambda(c, s, b, a, e, d) = \lambda_0(c, s, b, a)[1 + \beta_1 d \cdot \exp(\tau e + \nu \ln(a)) \cdot (1 + \sigma s)]$$


## Linear ERR model with modifying factors

$$\lambda(c, s, b, a, e, d) = \lambda_0(c, s, b, a) + \beta_1 d \cdot \exp(\tau e + \nu \ln(a)) \cdot (1 + \sigma s)$$

[Osaza Radiat Res 2012]

# Solid cancer excess relative risk among A-bomb survivors

## Solid cancer




Linear model:

$$\text{ERR} = 0.42 \text{ per Gy}$$
$$95\% \text{CI} = [0.32 ; 0.53]$$

[Ozasa et al, Rad Res 2012]


# INWORKS: Relative risk of non-CLL leukemia associated with red bone marrow dose



(Combined analysis of cohorts in France, US, UK, > 300,000 workers, follow-up 25y)

[Leuraud et al. Lancet Haematol 2015]


# INWORKS: Relative risk of non-CLL leukemia associated with red bone marrow dose



➔ ERR per Gy = 2.96 ; 90%CI [1.17 – 5.21]

[Leuraud et al. Lancet Haematol 2015]

# Uncertainties



- Characterisation of errors associated to exposure and dose
- Application of dose-error correction methods



## Content

- Epidemiology of radiation-induced risks
- Study types, terms and definitions
- Risk
- Dose-risk relationship
- Limits of low dose epidemiology
- Conclusion

# Limits of epidemiology at low doses

- **Low dose:** Low risks, RR close to 1
- **Epidemiological design:** need for well defined protocol and good data quality
- **Power:** large numbers needed to show small effects
- **Latency:** need long duration of follow-up (decades)
- **Baseline rates:** large variations between countries and populations
- **Multiple exposures:** background exposure, medical sources..
- **Multifactorial aetiology:** numerous non-radiation confounding factors
- **Errors in exposure assessment:** measurement errors
- **Mechanisms:** different at low and high dose
- **Low dose rate:** effect controlled by repairing systems / threshold ?

# Pre-requisites of low dose studies

- Avoid biases: Good quality designed protocol  
➔ **Cohort and case-control studies**
- To demonstrate low excess risks: Increasing the statistical power  
➔ **Large numbers, combined international studies**
- Latency period long and varying between cancer sites
- Modifying factors of the dose-risk relationship (age, time since exposure)  
➔ **Long duration of follow-up**
- Control for confounding factors  
➔ **Collection of additional data, nested studies**
- To limit the uncertainties: Precision of exposure data estimates  
➔ **Correction for measurement errors**



# Epidemiological studies at low dose and dose rate

## **Lung cancer risk and indoor radon: European Pooling study**

13 case-controls studies in European countries  
> 7000 cases (lung cancers) / > 14,000 controls  
reconstruction of past indoor radon concentration over 30 years  
control for smoking and other lung cancer risk factors  
(Darby 2005, Darby 2007)

## **Nuclear workers: INWORKS**

Cohorts from France, the UK and the USA  
> 308,000 workers, followed-up for 25 years  
> 66,000 deaths, including 20,000 from cancer  
external exposure: cumulated mean dose 25 mSv  
(Hamra 2015, Thierrychef 2015, Leuraud 2015, Richardson 2015)

## **Childhood CT scan: Epi-CT**

9 national cohort studies in European countries  
Children with CT-scan exam during childhood  
Objective: cohort of 1 million children  
(Pearce 2012, Krille 2015, Bosch de Basea 2015, Journy 2015)





## Content

- Epidemiology of radiation-induced risks
- Study types, terms and definitions
- Risk
- Dose-risk relationship
- Limits of low dose epidemiology
- **Conclusion**

# Causal Criteria

Evaluation of the existence of a causal association between cancer mortality and cumulative exposure to radon among French miners


Criteria	Lung cancer	Cancer of larynx
• strength of the association	+	+
• temporality	+	+
• dose-response gradient	+	-
• consistency	+	-
• plausibility	+	-
• coherence	+	-
• experimental evidence	+	-
• specificity	-	-

according to A Bradford Hill 1965

# Epidemiology at low doses: routes of improvement

- **International pooled analyses** (increasing power, standardization)
- **Multifactorial analyses** (complex exposures, other risk factors...)
- **Consideration of uncertainties** (error propagation)
- **Multidisciplinary integration** (epidemiology, dosimetry, statistics, biology)
- **Development of molecular epidemiology** (biomarkers to refine dosimetry, improve disease detection, assess inter-individual variability)

# Collaboration between epidemiology and dosimetry



Thank you  
for your attention